(NASDAQ: LUNG) Pulmonx's forecast annual revenue growth rate of 18.52% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.81%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Pulmonx's revenue in 2026 is $90,497,000.On average, 8 Wall Street analysts forecast LUNG's revenue for 2026 to be $3,916,993,732, with the lowest LUNG revenue forecast at $3,725,321,305, and the highest LUNG revenue forecast at $4,049,956,447. On average, 8 Wall Street analysts forecast LUNG's revenue for 2027 to be $4,640,179,122, with the lowest LUNG revenue forecast at $3,911,587,370, and the highest LUNG revenue forecast at $6,704,311,232.
In 2028, LUNG is forecast to generate $6,683,192,631 in revenue, with the lowest revenue forecast at $4,917,255,173 and the highest revenue forecast at $9,951,507,399.